Goldman Sachs Group Inc. Takes $3.21 Million Position in Mesoblast Limited $MESO

Key Points

• Goldman Sachs Group Inc. has purchased 257,143 shares of Mesoblast Limited, worth approximately $3,209,000, indicating significant investment interest in the company.
• Other institutional investors have also increased their positions in Mesoblast, with notable increases including a 1,503.3% rise from Bank of America Corp DE during the fourth quarter.
• Analysts have positive views on Mesoblast's stock, with Canaccord Genuity Group upgrading it to a "strong-buy" rating, while the average price target is set at $18.00.

Goldman Sachs Group Inc. bought a new stake in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 257,143 shares of the company's stock, valued at approximately $3,209,000. Goldman Sachs Group Inc. owned approximately 0.20% of Mesoblast at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its holdings in Mesoblast by 1,503.3% during the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock valued at $5,756,000 after purchasing an additional 272,595 shares in the last quarter. GAMMA Investing LLC lifted its stake in Mesoblast by 1,174.2% in the 1st quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock valued at $1,067,000 after buying an additional 78,802 shares in the last quarter. Summit X LLC lifted its stake in Mesoblast by 36.0% in the 1st quarter. Summit X LLC now owns 198,163 shares of the company's stock valued at $2,473,000 after buying an additional 52,508 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in Mesoblast by 104.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 71,891 shares of the company's stock worth $897,000 after buying an additional 36,700 shares in the last quarter. Finally, XY Capital Ltd purchased a new stake in Mesoblast during the 1st quarter worth approximately $346,000. Hedge funds and other institutional investors own 1.43% of the company's stock.

Mesoblast Trading Down 0.9%

Shares of MESO traded down $0.16 during midday trading on Monday, reaching $16.85. The company had a trading volume of 328,454 shares, compared to its average volume of 292,029. Mesoblast Limited has a 1-year low of $6.62 and a 1-year high of $22.00. The company has a quick ratio of 1.77, a current ratio of 1.99 and a debt-to-equity ratio of 0.11. The firm has a 50 day simple moving average of $15.09 and a 200-day simple moving average of $12.78.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MESO shares. Jefferies Financial Group lowered Mesoblast from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Canaccord Genuity Group upgraded Mesoblast to a "strong-buy" rating in a report on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $18.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.